Case Information
Settling Defendant |
Case Information |
Hetero – Valsartan |
A Settlement has been reached in an economic loss class action lawsuit against Hetero Drugs, Ltd., Hetero Labs Ltd., Hetero USA, Inc., and Camber Pharmaceuticals, Inc. (collectively “Hetero Defendants”). The Settlement resolves claims that Hetero Defendants violated state laws by manufacturing, distributing, selling and/or dispensing Valsartan or Valsartan containing drugs (“VCDs”) that were contaminated with a probable human carcinogen in the form of N-nitrosodimethylamine (“NDMA”), causing economic loss to the class. The Hetero Defendants have denied any wrongdoing, have denied that the amounts of NDMA or NDEA in the Valsartan and VCDs at issue were or could be carcinogenic, and have asserted various legal and factual defenses to the claims asserted on behalf of the Classes. |
Aurobindo – Irbesartan |
A Settlement has been reached in an economic loss class action lawsuit against Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., and Aurolife Pharma LLC (collectively, the “Aurobindo Defendants”). The Settlement resolves claims that Aurobindo Defendants violated state laws related to the manufacture, supply, distribution, marketing, and sale of finished dose using Aurobindo irbesartan API that was manufactured using Aurobindo’s IC Route of Synthesis allegedly containing nitrosamine impurities, causing economic losses to the class. The Aurobindo Defendants have denied any wrongdoing, have denied that the amounts of NDEA in the irbesartan and ICDs at issue were or could be carcinogenic, and have asserted various legal and factual defenses to the claims asserted on behalf of the Class. |
Vivimed – Losartan |
A Settlement has been reached in an economic loss class action lawsuit against Vivimed Life Sciences Pvt Ltd and Strides Pharma Science Limited (collectively, “Vivimed”). The Settlement is intended to fully, finally, and forever resolve, discharge, and settle the consumer and third-party payor class action claims for economic loss related to the sale of finished dose Losartan by Vivimed, or Vivimed’s repackager, Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. (“Heritage”), that was manufactured using API allegedly contaminated with nitrosamines including but not limited to NMBA. Vivimed has denied any wrongdoing, has denied that the amounts of NMBA in the Losartan and LCDs at issue were or could be carcinogenic, and have asserted various legal and factual defenses to the claims asserted on behalf of the Class. |
The settlements are part of a larger lawsuit called In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation, Case No. 1:19-md-02875 (MDL No. 2875) (the “Lawsuit”), currently pending in the United States District Court for the District of New Jersey (“the Court”). For more information, or to learn about the classes certified for a portion of the larger lawsuit, please visit www.ValsartanMedicationLawsuit.com.
Who Is a Class Member?
Settling Defendant |
Class Member Criteria |
Hetero – Valsartan |
You are a member of the Consumer Settlement Class if you are an individual in the United States and its territories and possessions who paid any amount of money for retail purchases of Valsartan finished drug formulations utilizing Hetero Process III Valsartan active pharmaceutical ingredient (“API”) which was sold between May 1, 2018 to July 31, 2018. |
Aurobindo – Irbesartan |
You are a member of the consumer Settlement Class if you are an individual in the United States and its territories and possessions who, from January 1, 2016 to the present, paid any amount of money for retail purchases of irbesartan finished drug formulations manufactured using Aurobindo irbesartan API that was manufactured using Aurobindo’s IC Route of Synthesis (“IC ROS Irbesartan”). |
Vivimed – Losartan |
You are a member of the consumer Settlement Class if you are an individual in the United States and its territories and possessions who paid any amount of money for retail purchases of Vivimed Losartan finished drug formulations sold under the following impacted National Drug Codes (“NDCs”): 23155-644-09; 23155-644-10; 23155-645-03; 23155-645-09; 23155-645-10; 23155-646-03; 23155-646-09; and 23155-646-10 (“Impacted NDCs”). |
Your Legal Rights and Options
Option and Deadline |
Your Legal Rights |
Submit a ClaimBY June 2, 2026 |
To receive a Settlement payment, you must submit a Claim Form. You can submit your Claim online at the Settlement website here or download a paper Claim Form and submit it by mail. Documentation should be submitted to support your claim, if possible. After you submit your claim, the Settlement Notice Administrator may contact you for proof of purchase from your pharmacy, if needed to approve your claim. |
Do Nothing |
If you do nothing, you will remain a part of the Class and Settlement. You will receive no payment under the Settlement and you will give up your rights to sue Vivimed about the issues in this case. |
Exclude Yourself from the SettlementBY June 2, 2026 |
Excluding yourself from the Settlement is the only option that allows you to pursue your own claims against Vivimed for the legal claims made in the Lawsuit. Choosing this option means you will not be bound by any future determination made in the Settlement; however, you will also not be eligible for a payment, if any are awarded. See question 12 for more information. |
Object to the SettlementBY June 2, 2026 |
If you do not like any part of the Settlement, you may write to the Court and explain your objection. You can not submit both an exclusion request and objection. You must remain a part of the Class to object. The Court will consider your objection at the Final Approval Hearing. If the Court grants Final Approval over your objection, you will give up your rights to sue Vivimed about the issues in this case. If you also wish to receive payment from the Settlement, you must submit a Claim Form. See Question 15 for more information. |
Dates and Deadlines
Claims Deadline
June 2, 2026
Exclusion Deadline
June 2, 2026
Objection Deadline
June 2, 2026
Fairness Hearing
June 30, 2026